This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Griggs, J. Articles by Hesketh, R. Search for Related Content PubMed PubMed Citation Articles by Griggs, J. Articles by Hesketh, R.

(American Journal of Pathology. 2002;160:1097-1103.)
© 2002 American Society for Investigative Pathology

Regular Articles

Inhibition of Proliferative Retinopathy by the Anti-Vascular Agent Combretastatin-A4

Jeremy Griggs^*, Jeremy N. Skepper, Gerry A. Smith^*, Kevin M. Brindle^*, James C. Metcalfe^* and Robin Hesketh^*

From the Departments of Biochemistry^*
andAnatomy,
University of Cambridge, Cambridge,United Kingdom

Retinal neovascularization occurs in a variety of diseases including diabetic retinopathy, the most common cause of blindness in the developed world. There is accordingly considerable incentive to develop drugs that target the aberrant angiogenesis associated with these conditions. Previous studies have shown that a number of anti-angiogenic agents can inhibit retinal neovascularization in a well-characterized murine model of ischemia-induced proliferative retinopathy. Combretastatin-A4 (CA-4) is an anti-vascular tubulin-binding agent currently undergoing clinical evaluation for the treatment of solid tumors. We have recently shown that CA-4 is not tumor-specific but elicits anti-vascular effects in nonneoplastic angiogenic vessels. In this study we have examined the capacity of CA-4 to inhibit retinal neovascularization in vivo. CA-4 caused a dose-dependent inhibition of neovascularization with no apparent side effects. The absence of vascular abnormalities or remnants of disrupted neovessels in retinas of CA-4-treated mice suggests an anti-angiogenic mechanism in this model, in contrast to the anti-vascular effects observed against established tumor vessels. Importantly, histological and immunohistochemical analyses indicated that CA-4 permitted the development of normal retinal vasculature while inhibiting aberrant neovascularization. These data are consistent with CA-4 eliciting tissue-dependent anti-angiogenic effects and suggest that CA-4 has potential in the treatment of nonneoplastic diseases with an angiogenic component.

This article has been cited by other articles:

				J. H. Chidlow Jr., W. Langston, J. J.M. Greer, D. Ostanin, M. Abdelbaqi, J. Houghton, A. Senthilkumar, D. Shukla, A. P. Mazar, M. B. Grisham, et al. Differential Angiogenic Regulation of Experimental Colitis Am. J. Pathol., December 1, 2006; 169(6): 2014 - 2030. [Abstract] [Full Text] [PDF]

				G. Zhang, R. G. Fahmy, N. diGirolamo, and L. M. Khachigian JUN siRNA regulates matrix metalloproteinase-2 expression, microvascular endothelial growth and retinal neovascularisation J. Cell Sci., August 1, 2006; 119(15): 3219 - 3226. [Abstract] [Full Text] [PDF]

				E. Escalona-Benz, M.-E. Jockovich, T. G. Murray, B. Hayden, E. Hernandez, W. Feuer, and J. J. Windle Combretastatin A-4 Prodrug in the Treatment of a Murine Model of Retinoblastoma Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 8 - 11. [Abstract] [Full Text] [PDF]

				C. Kanthou, O. Greco, A. Stratford, I. Cook, R. Knight, O. Benzakour, and G. Tozer The Tubulin-Binding Agent Combretastatin A-4-Phosphate Arrests Endothelial Cells in Mitosis and Induces Mitotic Cell Death Am. J. Pathol., October 1, 2004; 165(4): 1401 - 1411. [Abstract] [Full Text] [PDF]

				H. Nambu, R. Nambu, M. Melia, and P. A. Campochiaro Combretastatin A-4 Phosphate Suppresses Development and Induces Regression of Choroidal Neovascularization Invest. Ophthalmol. Vis. Sci., August 1, 2003; 44(8): 3650 - 3655. [Abstract] [Full Text] [PDF]

				P. E. Thorpe, D. J. Chaplin, and D. C. Blakey The First International Conference on Vascular Targeting: Meeting Overview Cancer Res., March 1, 2003; 63(5): 1144 - 1147. [Abstract] [Full Text] [PDF]